切换至 "中华医学电子期刊资源库"

中华损伤与修复杂志(电子版) ›› 2017, Vol. 12 ›› Issue (02) : 113 -117. doi: 10.3877/cma.j.issn.1673-9450.2017.02.008

所属专题: 文献

论著

新辅助化疗对浸润性乳腺癌分子标志物及分子分型的影响
陈圣1, 黄焰2, 王也3, 柳伟伟4, 张建华1, 王怀涛5, 董茂盛1,()   
  1. 1. 100088 北京,火箭军总医院普通外科
    2. 100071 北京,军事医学科学院附属医院乳腺外科
    3. 100029 北京,中日友好医院病理科
    4. 100850 军事医学科学院统计学教研室
    5. 100071 北京,军事医学科学院附属医院病理科
  • 收稿日期:2016-12-26 出版日期:2017-04-01
  • 通信作者: 董茂盛

Research of relationship between the change of molecular marker of breast cancer after neoadjuvant chemotherapy and therapeutic effect

Sheng Chen1, Yan Huang2, Ye Wang3, Weiwei Liu4, Jianhua Zhang1, Huaitao Wang5, Maosheng Dong1,()   

  1. 1. Department of General Surgery, the General Hospital of the PLA Rocket Force, Beijing 100088, China
    2. Department of Breast Surgery, Affiliated Hospital of Academy of Military Medical Sciences, Beijing 100071, China
    3. Department of Pathology, China-Japan Friendship Hospital, Beijing 100029, China
    4. Department of Statistics, Academy of Military Medical Sciences, Beijing 100850, China
    5. Department of Pathology, Affiliated Hospital of Academy of Military Medical Sciences, Beijing 100071, China
  • Received:2016-12-26 Published:2017-04-01
  • Corresponding author: Maosheng Dong
  • About author:
    Corresponding author: Dong Maosheng, Email:
引用本文:

陈圣, 黄焰, 王也, 柳伟伟, 张建华, 王怀涛, 董茂盛. 新辅助化疗对浸润性乳腺癌分子标志物及分子分型的影响[J/OL]. 中华损伤与修复杂志(电子版), 2017, 12(02): 113-117.

Sheng Chen, Yan Huang, Ye Wang, Weiwei Liu, Jianhua Zhang, Huaitao Wang, Maosheng Dong. Research of relationship between the change of molecular marker of breast cancer after neoadjuvant chemotherapy and therapeutic effect[J/OL]. Chinese Journal of Injury Repair and Wound Healing(Electronic Edition), 2017, 12(02): 113-117.

目的

研究乳腺癌新辅助化疗(NAC)(蒽环类联合紫衫类)过程中,雌激素受体(ER)、孕激素受体(PR)、HER2状态和Ki67值的变化,以及这些变化是否会对分子分型产生影响。

方法

回顾性分析从2011年11月到2015年6月期间在军事医学科学院附属医院行蒽环联合紫衫类NAC的137例浸润性乳腺癌患者。通过免疫组织化学方法测定NAC前后组织中ER、PR、HER2以及Ki67,并分为:Luminal A、Luminal B、三阴性和HER2阳性4种分子亚型。NAC前后分子标志物和分子分型的变化采用χ2检验或用Fisher确切概率法检验,并用Kappa检验对新辅助化疗前后的分子标志物及分子分型进行一致性检验。

结果

NAC前后ER、PR、HER2、Ki67的一致率分别为88.32%、83.21%、94.16%和75.91%。ER、PR、HER2在NAC前后变化差异均无统计学意义(P值均大于0.05)。在NAC后Ki67值平均数从35.75%降到了19.12%(P<0.05)。除性激素受体(HR)阳性,HER2阴性型的肿瘤之外,其余病例的分子分型在NAC前后的结果一致(P=0.488)。NAC前后分子分型的一致率为57.66%,Kappa值=0.4020。

结论

NAC会使浸润性乳腺癌Ki67的表达下降,并会影响HR阳性、HER2阴性型肿瘤的分子分型。

Objective

To research whether the changes of estrogen receptor (ER) , progesterone receptor (PR), HER2 associate with the efficacy, during the course of neoadjuvant chemotherapy(NAC)(anthracycline and docetaxel), and to research whether these changes will affect the molecular subtypes.

Methods

One hundred and thirty seven cases of patients given NAC (anthracycline and docetaxel) were retrospectively analyzed from November 2011 to June 2015 in the Affiliated Hospital of Academy of Military Medical Sciences. ER, PR, HER2 and Ki67 expression were tested by immunohistochemistry.According to immunohistochemistry results, the cases were divided into 4 molecular subtypes: Luminal A, Luminal B, triple negative and HER2 positive. Changes of ER, PR, HER2 and Ki67 expression and molecular subtypes after neoadjuvant chemotherapy were tested by Chi-square test and Fisher′s exact test, and Kappa test was used to test the consistency of molecular markers and molecular subtypes before and after NAC.

Results

Concordance rate of ER, PR, HER2 and Ki67 were 88.32%, 83.21%, 94.16% and 75.91 respectively.There was no significant difference in ER, PR and HER2 before and after NAC(P values were all more than 0.05). Ki67 average value had fallen from 35.75% to 19.12% after NAC(P<0.05). Molecular subtypes would haven not been changed after NAC, except for cases with Hormone receptors(HR)positive and HER2 negative (P=0.488). Concordance rate of molecular subtypes between pre-NAC biopsies and post-NAC specimens was 57.66% (Kappa=0.4020).

Conclusion

NAC leads to a decrease of Ki67 value in invasive breast cancer cases, and makes an effect on tumors with molecular subtype of HR+ , HER2-.

表1 浸润性乳腺癌患者NAC前后的病理特征(例)
表2 浸润性乳腺癌患者NAC前后分子标志物变化一致性的比较
表3 浸润性乳腺癌患者NAC前后4个分子亚型的一致性比较
表4 浸润性乳腺癌患者NAC前后5个分子亚型的一致性比较
1
Cockburn A, Yan J, Rahardja D, et al. Modulatory effect of neoadjuvant chemotherapy on biomarkers expression; assessment by digital image analysis and relationship to residual cancer burden in patients with invasive breast cancer[J]. Hum Pathol, 2014, 45(2):249-258.
2
Avci N, Deligonul A, Tolunay S, et al.Neoadjuvant chemotherapy-induced changes in immunohistochemical expression of estrogen receptor, progesterone receptor, HER2, and Ki-67 in patients with breast cancer[J]. J BUON, 2015, 20(1):45-49.
3
Hammond ME, Hayes DF, Dowsett M, et al. American society of clinical oncology/college of American pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer[J]. J Clin Oncol, 2010, 28(16):2784-2795.
4
杨文涛,步宏. 乳腺癌雌、孕激素受体免疫组织化学检测指南[J]. 中华病理学杂志,2012, 44(4):,237-239.
5
Long TH, Lawce H, Durum C, et al. The New Equivocal: Changes to HER2 FISH Results When Applying the 2013 ASCO/CAP Guidelines[J]. Am J Clin Pathol, 2015, 144(2):253-262.
6
Zhou X, Zhang J, Yun H, et al. Alterations of biomarker profiles after neoadjuvant chemotherapy in breast cancer: tumor heterogeneity should be taken into consideration[J]. Oncotarget, 2015, 6(34):36894-36902.
7
Lee HC, Ko H, Seol H, et al. Expression of Immunohistochemical Markers before and after Neoadjuvant Chemotherapy in Breast Carcinoma, and Their Use as Predictors of Response[J]. J Breast Cancer, 2013, 16(4):395-403.
8
陈圣,王也,柳伟伟,等. 空芯针远穿刺活检对确定乳腺癌分子亚型的诊断价值[J]. 中华普通外科杂志,2017, 32(1):49-53.
9
Chen X, Sun L, Mao Y, et al. Preoperative core needle biopsy is accurate in determining molecular subtypes in invasive breast cancer[J]. BMC Cancer, 2013, 13:390.
10
刘艳,张霄蓓,余峰,等. 新辅助化疗前后Ki-67的表达改变在预测不同分子分型乳腺癌化疗疗效中的作用[J]. 中华肿瘤杂志,2014, 36(9):671-676.
11
Jones RL, Salter J, A′Hem R, et al.The prognostic significance of Ki67 before and after neoadjuvant chemotherapy in breast cancer[J]. Breast Cancer Res Treat, 2009, 116(1):53-68.
12
Lee J, Im YH, Lee SH,et al.Evaluation of ER and Ki-67 proliferation index as prognostic factors for survival following neoadjuvant chemotherapy with doxorubicin/docetaxel for locally advanced breast cancer[J]. Cancer Chemother Pharmacol, 2008, 61(4):569-577.
[1] 李洋, 蔡金玉, 党晓智, 常婉英, 巨艳, 高毅, 宋宏萍. 基于深度学习的乳腺超声应变弹性图像生成模型的应用研究[J/OL]. 中华医学超声杂志(电子版), 2024, 21(06): 563-570.
[2] 周荷妹, 金杰, 叶建东, 夏之一, 王进进, 丁宁. 罕见成人肋骨郎格汉斯细胞组织细胞增生症被误诊为乳腺癌术后骨转移一例[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(06): 380-383.
[3] 河北省抗癌协会乳腺癌专业委员会护理协作组. 乳腺癌中心静脉通路护理管理专家共识[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(06): 321-329.
[4] 刘晨鹭, 刘洁, 张帆, 严彩英, 陈倩, 陈双庆. 增强MRI 影像组学特征生境分析在预测乳腺癌HER-2 表达状态中的应用[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(06): 339-345.
[5] 张晓宇, 殷雨来, 张银旭. 阿帕替尼联合新辅助化疗对三阴性乳腺癌的疗效及预后分析[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(06): 346-352.
[6] 邱琳, 刘锦辉, 组木热提·吐尔洪, 马悦心, 冷晓玲. 超声影像组学对致密型乳腺背景中非肿块型乳腺癌的诊断价值[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(06): 353-360.
[7] 高俊颖, 张海洲, 区泓乐, 孙强. FOLFOX-HAIC 为基础的肝细胞癌辅助转化治疗的应用进展[J/OL]. 中华普通外科学文献(电子版), 2024, 18(06): 457-463.
[8] 高杰红, 黎平平, 齐婧, 代引海. ETFA和CD34在乳腺癌中的表达及与临床病理参数和预后的关系研究[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 64-67.
[9] 韩萌萌, 冯雪园, 马宁. 乳腺癌改良根治术后桡神经损伤1例[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 117-118.
[10] 张志兆, 王睿, 郜苹苹, 王成方, 王成, 齐晓伟. DNMT3B与乳腺癌预后的关系及其生物学机制[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 624-629.
[11] 王玲艳, 高春晖, 冯雪园, 崔鑫淼, 刘欢, 赵文明, 张金库. 循环肿瘤细胞在乳腺癌新辅助及术后辅助治疗中的应用[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 630-633.
[12] 赵林娟, 吕婕, 王文胜, 马德茂, 侯涛. 超声引导下染色剂标记切缘的梭柱型和圆柱型保乳区段切除术的效果研究[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 634-637.
[13] 林逸, 钟文龙, 李锴文, 何旺, 林天歆. 广东省医学会泌尿外科疑难病例多学科会诊(第15期)——转移性膀胱癌的综合治疗[J/OL]. 中华腔镜泌尿外科杂志(电子版), 2024, 18(06): 648-652.
[14] 王誉英, 刘世伟, 王睿, 曾娅玲, 涂禧慧, 张蒲蓉. 老年乳腺癌新辅助治疗病理完全缓解的预测因素分析[J/OL]. 中华临床医师杂志(电子版), 2024, 18(07): 641-646.
[15] 崔军威, 蔡华丽, 胡艺冰, 胡慧. 亚甲蓝联合金属定位夹及定位钩针标记在乳腺癌辅助化疗后评估腋窝转移淋巴结的临床应用价值探究[J/OL]. 中华临床医师杂志(电子版), 2024, 18(07): 625-632.
阅读次数
全文


摘要